ARS Pharmaceuticals Q3 2026 Results: Net Loss of $35.6M, Loss Narrows
ARS Pharmaceuticals is focused on the commercialization of neffy, its intranasal epinephrine product, following recent regulatory approvals. The company reported 100,528,400 shares of common stock outstanding as of November 3, 2026, and is classified as a non-accelerated filer and smaller reporting company.
- Key figure
- Net loss $35.6M